1-8 of 8
Melih Aktan
Close
Sort by
Journal Articles

The Whole Exome Analysis and Clinical Relevance in Patients with Atypical Hemolytic Uremic Syndrome

Mustafa Nuri Yenerel, Yasar Caliskan, Alaattin Yildiz, Sedat Karadeniz, Aydin Turkmen, Mehmet Seit Kayacan, Tufan Tukek, Murat Köse, Melih Aktan, Meliha Nalcaci
Journal: Blood
Blood (2017) 130 (Supplement 1): 3618.
https://doi.org/10.1182/blood.V130.Suppl_1.3618.3618
Published: 2017
Journal Articles

Safety of Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Primary Analysis of the Phase 3b GREEN Study

Stephan Stilgenbauer, MD PhD, Melih Aktan, Christelle M Ferra Coll, Caroline Dartigeas, Jens Kisro, Marco Montillo, MD, João Raposo, Jean-Louis Merot, Susan Robson, Ekaterina Gresko, Francesc Bosch, Robin Foà, MD, Véronique Leblond
Journal: Blood
Blood (2017) 130 (Supplement 1): 4309.
https://doi.org/10.1182/blood.V130.Suppl_1.4309.4309
Published: 2017
Journal Articles

Circulating Endothelial Progenitor Cells and Their Relation to Thrombosis in Paroxysmal Nocturnal Hemoglobinuria

Esra Turan Erkek, Esra Nazligul, Meliha Nalcaci, Melih Aktan, Mustafa Nuri Yenerel
Journal: Blood
Blood (2015) 126 (23): 4535.
https://doi.org/10.1182/blood.V126.23.4535.4535
Published: 2015
Journal Articles

The Importance of Eculizumab in Patients with Atypical Hemolytic Uremic Syndrome: Single Center Experience

Mustafa Nuri Yenerel, MD, Melih Aktan, Alaattin Yildiz, Yasar Caliskan, Meliha Nalcaci
Journal: Blood
Blood (2014) 124 (21): 2777.
https://doi.org/10.1182/blood.V124.21.2777.2777
Published: 2014
Journal Articles

Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe).

Veronique Leblond, Kamel Laribi, MD, Osman Ilhan, MD, Melih Aktan, Ali Unal, MD, Saad M B Rassam, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, MRCP, FRCPath, Tom Widenius, MD, PhD, Peter Johansson, MD, PhD, Joao Raposo, Balkis Meddeb, Carol Moreno, MD, PhD, Stephan H.K. Oertel, MD, Anne-Sophie Michallet, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2744.
https://doi.org/10.1182/blood.V120.21.2744.2744
Published: 2012
Journal Articles

Can Activation Induced Cytidine Deaminase Lead to Genetic Instability in Bcr-Abl Negative Myeloproliferative Neoplasms?

Hasan Dermenci, Aynur Daglar, Basak Peker Akadam, Veysel Sabri Hancer, Yusuf Gelmez, Melih Aktan, Meliha Nalcaci, Akif S. Yavuz
Journal: Blood
Blood (2012) 120 (21): 5056.
https://doi.org/10.1182/blood.V120.21.5056.5056
Published: 2012
Journal Articles

Does Previous Interferon Use Have Negative Effect on Imatinib Response in Chronic Myeloid Leukemia (CML)? A Single Center Study.

Mustafa Yenerel, Reyhan Diz-Kucukkaya, Naciye Demirel, Mesut Ayer, Selim Yavuz, Sevgi Besisik, Melih Aktan, Meliha Nalcaci, Deniz Sargin, Tanju Atamer, Yuksel Pekcelen, Guncag Dincol
Journal: Blood
Blood (2006) 108 (11): 4821.
https://doi.org/10.1182/blood.V108.11.4821.4821
Published: 2006
Journal Articles

ERGIC-53 Gene Structure and Mutation Analysis in 19 Combined Factors V and VIII Deficiency Families

William C. Nichols, Valeri H. Terry, Matthew A. Wheatley, Angela Yang, Ariella Zivelin, Nicola Ciavarella, Caterina Stefanile, Tadashi Matsushita, Hidehiko Saito, Norma B. de Bosch, Arlette Ruiz-Saez, Argimiro Torres, Arthur R. Thompson, Donald I. Feinstein, Gilbert C. White, Claude Negrier, Christine Vinciguerra, Melih Aktan, Randal J. Kaufman, David Ginsburg, Uri Seligsohn
Journal: Blood
Blood (1999) 93 (7): 2261–2266.
https://doi.org/10.1182/blood.V93.7.2261
Published: 1999